ATE361368T1 - Von alphavirus abgeleitete vektoren als impfstoffe gegen eine paramyxovirusinfektion - Google Patents

Von alphavirus abgeleitete vektoren als impfstoffe gegen eine paramyxovirusinfektion

Info

Publication number
ATE361368T1
ATE361368T1 AT98942413T AT98942413T ATE361368T1 AT E361368 T1 ATE361368 T1 AT E361368T1 AT 98942413 T AT98942413 T AT 98942413T AT 98942413 T AT98942413 T AT 98942413T AT E361368 T1 ATE361368 T1 AT E361368T1
Authority
AT
Austria
Prior art keywords
vector
protein
host
alphavirus
rsv
Prior art date
Application number
AT98942413T
Other languages
English (en)
Inventor
Mark Parrington
Original Assignee
Sanofi Pasteur Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Ltd filed Critical Sanofi Pasteur Ltd
Application granted granted Critical
Publication of ATE361368T1 publication Critical patent/ATE361368T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT98942413T 1997-09-04 1998-09-03 Von alphavirus abgeleitete vektoren als impfstoffe gegen eine paramyxovirusinfektion ATE361368T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/923,558 US6060308A (en) 1997-09-04 1997-09-04 RNA respiratory syncytial virus vaccines

Publications (1)

Publication Number Publication Date
ATE361368T1 true ATE361368T1 (de) 2007-05-15

Family

ID=25448878

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98942413T ATE361368T1 (de) 1997-09-04 1998-09-03 Von alphavirus abgeleitete vektoren als impfstoffe gegen eine paramyxovirusinfektion

Country Status (9)

Country Link
US (2) US6060308A (de)
EP (1) EP1009846B1 (de)
JP (1) JP2001514857A (de)
AT (1) ATE361368T1 (de)
AU (1) AU742046B2 (de)
BR (1) BR9815642B1 (de)
CA (1) CA2301891C (de)
DE (1) DE69837708T2 (de)
WO (1) WO1999011808A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US20030054505A1 (en) * 1997-09-26 2003-03-20 Hong Jin Recombinant rsv expression systems and vaccines
US7465574B2 (en) * 1994-09-30 2008-12-16 Medimmune, Llc Recombinant RSV virus expression systems and vaccines
US6451592B1 (en) 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
US6060308A (en) * 1997-09-04 2000-05-09 Connaught Laboratories Limited RNA respiratory syncytial virus vaccines
US6830748B1 (en) * 1997-09-26 2004-12-14 Medimmune Vaccines, Inc. Recombinant RSV virus expression systems and vaccines
US20030180257A1 (en) * 1997-11-14 2003-09-25 Mark Parrington Alphavirus vectors for paramyxovirus vaccines
EP1707633A1 (de) * 1997-11-14 2006-10-04 Sanofi Pasteur Limited Alphavirus-Vektoren als Impfstoffe gegen Paramyxovirus
US8647864B2 (en) 1999-04-14 2014-02-11 Novartis Ag Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
DE60135983D1 (de) 2000-05-31 2008-11-13 Novartis Vaccines & Diagnostic Verfahren zur reinigung von alphaviralen replikon partikeln
KR100481879B1 (ko) * 2001-02-08 2005-04-11 크레아젠 주식회사 (+)-단일쇄 ｒｎａ 재조합 벡터내 삽입 서열의 유전적 안정성을 증가시키는 방법
EP2848692B1 (de) 2004-05-21 2017-08-16 Novartis Vaccines and Diagnostics, Inc. Alphavirus-Vektoren für Influenzavirus-Impfstoffe
WO2009128949A2 (en) * 2008-04-18 2009-10-22 Vaxinnate Corporation Compositions of dengue viral proteins and methods of use
AU2009316680B2 (en) * 2008-11-18 2016-03-24 Takeda Vaccines, Inc. RSV F VLPs and methods of manufacture and use thereof
PE20121541A1 (es) * 2009-06-24 2012-12-21 Glaxosmithkline Biolog Sa Antigenos de virus de sincicio respiratorio recombinantes
EP4218799A1 (de) 2009-07-15 2023-08-02 GlaxoSmithKline Biologicals S.A. Rsv-f-proteinzusammensetzungen und verfahren zur herstellung davon
EP2590670B1 (de) 2010-07-06 2017-08-23 GlaxoSmithKline Biologicals SA Methoden zur auslösung einer immunantwort durch verabreichung von rna
RS54489B1 (en) * 2010-07-06 2016-06-30 Glaxosmithkline Biologicals Sa LIPOSOMS WITH LIPIDS THAT HAVE IMPROVED PKA VALUE FOR RNA RELEASE
LT2590676T (lt) 2010-07-06 2016-10-25 Glaxosmithkline Biologicals Sa Viriono tipo išnešiojančios dalelės, skirtos besireplikuojančioms rnr molekulėms
PT2591114T (pt) 2010-07-06 2016-08-02 Glaxosmithkline Biologicals Sa Imunização de mamíferos de grande porte com doses baixas de arn
US9770463B2 (en) * 2010-07-06 2017-09-26 Glaxosmithkline Biologicals Sa Delivery of RNA to different cell types
PL3970742T3 (pl) 2010-08-31 2022-09-19 Glaxosmithkline Biologicals S.A. Pegylowane liposomy do dostarczania rna kodującego immunogen
US20140030292A1 (en) 2010-10-11 2014-01-30 Novartis Ag Antigen delivery platforms
LT3275892T (lt) 2011-05-13 2020-04-10 Glaxosmithkline Biologicals S.A. Struktūros prieš suliejimą rsv f antigenai
IL280771B2 (en) 2011-06-08 2024-03-01 Shire Human Genetic Therapies Preparations of lipid nanoparticles and methods for administration of mRNA
US11896636B2 (en) 2011-07-06 2024-02-13 Glaxosmithkline Biologicals Sa Immunogenic combination compositions and uses thereof
WO2022099003A1 (en) 2020-11-06 2022-05-12 Sanofi Lipid nanoparticles for delivering mrna vaccines

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5169628A (en) 1988-04-22 1992-12-08 The Upjohn Company Chimeric glycoproteins containing immunogenic segments of human parainfluenza virus type 3
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
GB9406498D0 (en) 1994-03-31 1994-05-25 Smithkline Beecham Biolog Novel compounds
WO1996017072A2 (en) * 1994-11-30 1996-06-06 Chiron Viagene, Inc. Recombinant alphavirus vectors
US5614372A (en) * 1995-02-24 1997-03-25 Lilja; Hans Early detection of prostate cancer (CAP) by employing prostate specific antigen (PSA) and human glandular kallikrein (hGK-1)
US6019980A (en) * 1995-06-07 2000-02-01 Connaught Laboratories Limited Nucleic acid respiratory syncytial virus vaccines
US6060308A (en) * 1997-09-04 2000-05-09 Connaught Laboratories Limited RNA respiratory syncytial virus vaccines

Also Published As

Publication number Publication date
AU742046B2 (en) 2001-12-13
BR9815642B1 (pt) 2013-09-17
JP2001514857A (ja) 2001-09-18
AU9056998A (en) 1999-03-22
EP1009846A1 (de) 2000-06-21
US6060308A (en) 2000-05-09
CA2301891A1 (en) 1999-03-11
DE69837708D1 (de) 2007-06-14
US6428324B1 (en) 2002-08-06
DE69837708T2 (de) 2008-01-10
CA2301891C (en) 2010-01-19
WO1999011808A1 (en) 1999-03-11
BR9815642A (pt) 2002-12-31
EP1009846B1 (de) 2007-05-02

Similar Documents

Publication Publication Date Title
ATE361368T1 (de) Von alphavirus abgeleitete vektoren als impfstoffe gegen eine paramyxovirusinfektion
DK0724642T4 (da) Nucleinsyrevektor, sammensætning indeholdende en sådan vektor og vaccine til immunisering mod hepatitis
CY1116761T1 (el) Αλληλουχιες κυκλοϊου σχετικου με την νοσο απισχνασης του χοιριδιου (map)
BR9608615A (pt) Vacinas de vírus sincicial respiratório de ácido nucléico
DE69829668D1 (de) Herstellung und verwendung von rekombinanten influenza a virus m2 konstruktionen und impstoffe
BR7908410A (pt) Meio para deteccao de anticorpos de vhb no soro do sangue,e processo para deteccao da presenca da infeccao por virus da hepatite b em seres humanos
TR200401186T4 (tr) Rekombinant bir RNA-virüs oluşumunu yönlendirebilen nükleik asit sekansları içerikli suni kromozom yapıları.
SE9003978D0 (sv) Dna expressionssystem baserade paa ett virus replikon
WO2004085633A8 (en) A novel human virus causing severe acute respiratory syndrome (sars) and uses thereof
BR9815285A (pt) Vetores alfavìrus para vacina de paramixovìrus
BR9815496A (pt) Vacinas de ácido nucléico que codificam proteìna gde vìrus sincicial respiratório
US20160228531A1 (en) Treatment of hepatitis d virus infections by redirection of t cells
BR9508645A (pt) Vacina da peritonite infecciosa felina
AU2973800A (en) Dna vaccines against hantavirus infections
ATE269064T1 (de) Impfstoffe gegen den hepatitis b und c virus
ATE414905T1 (de) Diabetesmodell
BR9915970A (pt) Vìrus recombinante expressando dna exógenocodificando cd80 felino, ctla-4 felino ou cd86 felinoe usos do mesmo
FR2830019B1 (fr) Molecules d'acides nucleiques d'hdv, leurs fragments et leurs apllications
PT1254663E (pt) Agente antiviral
DE69925927D1 (de) Mutmassliches 98 kd protein des aussenmembrans von chlamydia und dafür kodierende dns sowie deren verwendung
CA2086577A1 (en) Potential target for immunotherapy to prevent replication of hiv (aids virus) in humans: cdna and protein for a putative regulator of hiv gag polyprotein expression reconstructed from the antisense strand of human p53 gene
Binger et al. Recombinant coccidiosis vaccines

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties